Physitrack Q2 FY26 net result returns to profit of EUR 0; revenue rises 8% to EUR 3.4 million vs Q2 FY25

  • Physitrack Q2 2026 revenue rose 8% to EUR 3.4 million; net income swung to EUR 0.0 million.
  • EBITDA climbed 13% to EUR 1.1 million; free cash flow from continuing operations turned negative at EUR (0.2) million.
  • Lifecare revenue increased 11% to EUR 3.1 million; ARR rose 7% to EUR 12.7 million.
  • Wellness revenue fell 14% to EUR 0.3 million; adjusted EBITDA improved to EUR 0.1 million.
  • Launched Remote Therapeutic Monitoring in the U.S. with first paying customers live; share buyback starts in August 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Physitrack plc published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.